• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4)

    3/4/24 9:50:46 PM ET
    $MDRX
    EDP Services
    Technology
    Get the next $MDRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    STONEHILL CAPITAL MANAGEMENT LLC

    (Last) (First) (Middle)
    320 PARK AVENUE, 26TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Veradigm Inc. [ MDRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/28/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.01 per share 02/28/2024 P 2,679,000 A $6.81 7,766,686 I See Footnotes(1)(2)
    Common Stock, par value $0.01 per share 02/28/2024 P 3,021,000 A $6.81 8,758,176 I See Footnotes(2)(3)
    Common Stock, par value $0.01 per share 02/29/2024 P 246,750 A $6.09(4) 8,013,436 I See Footnotes(1)(2)
    Common Stock, par value $0.01 per share 02/29/2024 P 278,250 A $6.09(4) 9,036,426 I See Footnotes(2)(3)
    Common Stock, par value $0.01 per share 03/01/2024 P 1,599,150 A $6(5) 9,612,586 I See Footnotes(1)(2)
    Common Stock, par value $0.01 per share 03/01/2024 P 2,398,725 A $6(5) 11,435,151 I See Footnotes(2)(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    STONEHILL CAPITAL MANAGEMENT LLC

    (Last) (First) (Middle)
    320 PARK AVENUE, 26TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    STONEHILL INSTITUTIONAL PARTNERS LP

    (Last) (First) (Middle)
    C/O STONEHILL CAPITAL MANAGEMENT LLC,
    320 PARK AVENUE, 26TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    MOTULSKY JOHN

    (Last) (First) (Middle)
    C/O STONEHILL CAPITAL MANAGEMENT LLC,
    320 PARK AVENUE, 26TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Sacks Jonathan S

    (Last) (First) (Middle)
    C/O STONEHILL CAPITAL MANAGEMENT LLC,
    320 PARK AVENUE, 26TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    SISITSKY PETER

    (Last) (First) (Middle)
    C/O STONEHILL CAPITAL MANAGEMENT LLC,
    320 PARK AVENUE, 26TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    THOYER MICHAEL

    (Last) (First) (Middle)
    C/O STONEHILL CAPITAL MANAGEMENT LLC,
    320 PARK AVENUE, 26TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Stern Michael Lenard

    (Last) (First) (Middle)
    C/O STONEHILL CAPITAL MANAGEMENT LLC,
    320 PARK AVENUE, 26TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Held directly by Stonehill Master Fund Ltd (the "Master Fund").
    2. Stonehill Capital Management LLC ("Management") is the manager of Stonehill Institutional Partners, L.P. (the "Fund") and the Master Fund. John Motulsky, Jonathan Sacks, Peter Sisitsky, Michael Thoyer, Michael Stern, Samir Arora and Garrett Zwahlen are the managing members of Management. The reporting persons disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interests therein, and this report shall not be deemed an admission that the reporting persons are the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
    3. Held directly by the Fund.
    4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.00 to $6.1474, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1 and 5 to this Form 4.
    5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.9310 to $6.0947, inclusive.
    /s/ Stonehill Capital Management LLC, by Paul Malek, Authorized Signatory 03/04/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDRX

    DatePrice TargetRatingAnalyst
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    1/3/2024$11.00Equal Weight
    Barclays
    7/6/2023Buy → Hold
    Argus
    4/12/2023$13.00Equal-Weight
    Stephens
    2/1/2023$17.00 → $18.50Overweight → Neutral
    Piper Sandler
    12/7/2022$26.00Hold → Buy
    Argus
    11/9/2022$22.00 → $23.00Neutral → Buy
    Goldman
    11/4/2022$17.00Overweight
    Piper Sandler
    More analyst ratings

    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Syracuse Orthopedic Specialists Selects Veradigm to Achieve Exceptional Financial Health and Operational Efficiency

      Veradigm to provide a comprehensive solution set to optimize revenue cycle and coding processes Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that Syracuse Orthopedic Specialists has selected elements from the Veradigm solution suite, Veradigm Revenue Cycle Services and Coding Services designed to support growth, improve cash flow and reduce costs. Syracuse Orthopedic Specialists, located near Syracuse, NY, provides total orthopedic care to the surrounding regions, and is currently utilizing Veradigm Revenue Analytics, Veradigm Practice Management and Veradigm Payerpath. Veradigm Revenue Cycle Services provides a robust suite of solu

      4/2/25 8:01:00 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services

    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4) (Amendment)

      4/A - Veradigm Inc. (0001124804) (Issuer)

      3/15/24 5:16:45 PM ET
      $MDRX
      EDP Services
      Technology
    • Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      3/4/24 9:50:46 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Financials

    Live finance-specific insights

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Veradigm to Release Financial Update March 18th and Host Investor Call March 19th

      Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a financial update after the close of regular stock market hours on March 18, 2025. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on March 19, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Tuesday, March 18, 2025. The announcement will also be available at the Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations we

      3/13/25 9:57:00 PM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review

      Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti

      1/30/25 4:02:00 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    SEC Filings

    See more
    • SEC Form 8-K filed by Veradigm Inc.

      8-K - Veradigm Inc. (0001124804) (Filer)

      4/22/25 4:23:28 PM ET
      $MDRX
      EDP Services
      Technology
    • SEC Form 8-K filed by Veradigm Inc.

      8-K - Veradigm Inc. (0001124804) (Filer)

      4/17/25 5:02:25 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form 8-K/A filed by Veradigm Inc.

      8-K/A - Veradigm Inc. (0001124804) (Filer)

      4/10/25 4:10:53 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G filed by Veradigm Inc.

      SC 13G - Veradigm Inc. (0001124804) (Subject)

      11/14/24 4:05:58 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

      SC 13G/A - Veradigm Inc. (0001124804) (Subject)

      11/14/24 1:11:13 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

      SC 13G/A - Veradigm Inc. (0001124804) (Subject)

      11/8/24 10:29:29 AM ET
      $MDRX
      EDP Services
      Technology
    • CEO Langan Thomas covered exercise/tax liability with 1,893 shares, decreasing direct ownership by 0.57% to 327,528 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      5/5/25 4:08:52 PM ET
      $MDRX
      EDP Services
      Technology
    • CEO Langan Thomas covered exercise/tax liability with 2,481 shares, decreasing direct ownership by 0.75% to 329,421 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      4/3/25 4:55:05 PM ET
      $MDRX
      EDP Services
      Technology
    • SVP & Chief HR Officer Hammond Lisa covered exercise/tax liability with 227 shares, decreasing direct ownership by 0.19% to 119,648 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      4/2/25 4:57:39 PM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously

      3/19/24 7:50:39 AM ET
      $MDRX
      EDP Services
      Technology
    • Barclays initiated coverage on Veradigm with a new price target

      Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00

      1/3/24 8:00:02 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm downgraded by Argus

      Argus downgraded Veradigm from Buy to Hold

      7/6/23 9:00:49 AM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Sprinklr Set to Join S&P SmallCap 600

      NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea

      2/28/24 5:50:00 PM ET
      $CXM
      $MDRX
      $SPGI
      Computer Software: Prepackaged Software
      Technology
      EDP Services
      Finance: Consumer Services